Roth Capital Affirms Ligand Pharma (LGND) Following Solid Q2 Revenue Results for Promacta (NVS)
Tweet Send to a Friend
Roth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) with a Buy rating and $147 price target after Novartis (NYSE: NVS) announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
